ClearPoint Neuro reported second quarter revenue of $10.9 million, an 18% increase year-over-year, which beat analyst estimates of $10.45 million. The company reported a net loss of $0.38 per share, missing the consensus estimate of a $0.29 loss. The revenue growth was driven by a strong performance in the Neurosurgery navigation and therapy segment, which offset a decline in the key Biologics and Drug Delivery segment. Citing a shift in investment priorities, the company adjusted its full-year 2026 revenue guidance to a range of $48.0 million to $52.0 million.
Key Highlights
- Second quarter revenue grew 18% year-over-year to $10.9 million, primarily driven by the acquisition of the IRRAflow Portfolio.
- The key Biologics and Drug Delivery segment saw revenue decline 15% to $4.0 million due to the timing of biopharma customer orders.
- The Neurosurgery navigation and therapy segment posted strong results with revenue increasing 62% to $5.6 million.
- ClearPoint lowered its full-year 2026 revenue guidance to a range of $48.0 million to $52.0 million to focus investments on clinical support and development ahead of potential partner drug commercializations.